UNSPSC 51241522: Dorzolamide/timolol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP105. This VA Drug Class (OP105) classifies this compound as belonging to the group ANTIGLAUCOMA COMBINATIONS, TOPICAL OPHTHALMIC.

UNSPSC 51241522 Dorzolamide/timolol is a Commodity code capturing ophthalmic pharmaceutical products that state and local governments procure through cooperative purchasing vehicles and direct pharmaceutical supply agreements. The recent activity reflects state and local demand for generic and branded pharmaceutical inventory managed through multi-state cooperative contracts that aggregate purchasing across participating jurisdictions to achieve volume pricing and standardized supply-chain logistics.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving state and local government facilities across participating states including Oregon. MMCAP requires vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and to provide comprehensive pricing with specific National Drug Codes, SKUs, UPCs, generic descriptions, strength, dosage form, trade names, packaging configurations, and manufacturing locations. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place, and maintain insurance coverage including commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000. The contract term is two years for new responders with optional extensions at MMCAP's sole discretion, with awarded vendors effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and the remainder on EDI capability, administrative fee compliance, and data format requirements.